All treatments may have complications, with either ineffective relief of symptoms or worsening of the condition.

Neoplasm (e.g., rheumatoid nodule)

Foot health facts: Foot and ankle conditions. 2009. Available in Spanish and English from the

Disclaimer

Financial Disclosures/Conflicts of Interest

Guideline Developer(s)

Institute of Medicine (IOM) National Healthcare Quality Report Categories

Benefits/Harms of Implementing the Guideline Recommendations

Type of Evidence Supporting the Recommendations

Clinical Algorithm(s)

Major Recommendations

Recommendations

Cost Analysis

Methods Used to Formulate the Recommendations

Description of Methods Used to Collect/Select the Evidence

Methodology

Major Outcomes Considered

Target Population

Intended Users

Disease/Condition(s)

Guideline Category

Clinical Specialty

Scope

Foot and Ankle Surgeons consumer Web site

NGC banner

NGC-7479

NGC banner

Guideline Title


Bibliographic Source(s)


Guideline Status

This is the current release of the guideline.

Scope

Disease/Condition(s)

Morton's intermetatarsal neuroma

Guideline Category

Diagnosis

Evaluation

Management

Treatment

Clinical Specialty

Family Practice

Neurological Surgery

Orthopedic Surgery

Pathology

Podiatry

Radiology

Rheumatology

Intended Users

Physicians

Podiatrists

Guideline Objective(s)

To provide recommendations for the diagnosis and treatment of Morton's intermetatarsal neuroma

Target Population

Patients with Morton's intermetatarsal neuroma

Interventions and Practices Considered

Diagnosis/Evaluation

1. Comprehensive history and physical examination including review of symptoms such as burning pain, tingling/numbness, sharp or radiating pain, sensory deficit

2. Differential diagnosis

3. Clinical maneuvers such as Mulder's sign, Gauthier's test, Bratkowski test

4. Diagnostic testing including radiographs, ultrasound, magnetic resonance imaging (MRI)

Management/Treatment

1. Initial treatment including pads, footwear alteration, and injection therapy

2. Surgical treatment including excision, decompression, and cryogenic neuroablation

3. Re-assessment for continued symptoms
**Major Outcomes Considered**

Treatment complications

**Methodology**

**Methods Used to Collect/Select the Evidence**

Searches of Electronic Databases

**Description of Methods Used to Collect/Select the Evidence**

A search of medical literature was performed using the EndNote, Medline/PubMed, National Library of Medicine, and Science Direct databases from 1950 to 2008. The terms used were Morton’s neuroma and intermetatarsal neuroma.

**Number of Source Documents**

Not stated

**Methods Used to Assess the Quality and Strength of the Evidence**

Weighting According to a Rating Scheme (Scheme Not Given)

**Rating Scheme for the Strength of the Evidence**

Not applicable

**Methods Used to Analyze the Evidence**

Review

**Description of the Methods Used to Analyze the Evidence**

Not stated

**Methods Used to Formulate the Recommendations**

Expert Consensus

**Description of Methods Used to Formulate the Recommendations**

Not stated

**Rating Scheme for the Strength of the Recommendations**

Not applicable

**Cost Analysis**

A formal cost analysis was not performed and published cost analyses were not reviewed.

**Method of Guideline Validation**

External Peer Review

Internal Peer Review

**Description of Method of Guideline Validation**

Not stated

**Recommendations**

**Major Recommendations**

The recommendations for the diagnosis and treatment of Morton's intermetatarsal neuroma are presented in the form of an algorithm with accompanying annotations. An algorithm is provided for Morton's Intermetatarsal Neuroma. Annotations follow.

**Morton’s Intermetatarsal Neuroma (Pathway 4)**

Morton's intermetatarsal neuroma is a compression neuropathy of the common digital nerve. It is most commonly seen in the third intermetatarsal space, but it also can be seen in other intermetatarsal spaces (see Figures 1 and 2 in the original guideline document).

**Significant History (Pathway 4, Node 1)**

The subjective history reported by the patient is usually characteristic for this entity. The patient may complain of numbness and tingling, and/or radiating, burning pain. The pain often is localized at the plantar aspect of the respective intermetatarsal space, but it can radiate into the adjacent toes. Patients frequently describe a "lump" on the bottom of their foot or a feeling of walking on a rolled-up or wrinkled sock. The symptoms may increase with weightbearing and activity. Closed-toed shoes and especially tight-fitting footwear can increase the symptoms.
Patients report relief of symptoms upon removing or changing their shoes. They also may get relief from massaging the foot and moving the toes.

**Significant Findings (Pathway 4, Node 2)**

Objective findings are unique to Morton's neuroma and can provide further insight to aid the clinician in the diagnostic process. Although patients frequently describe numbness, a sensory deficit may or may not be present on examination. The clinical presentation may demonstrate a plying or divergence of the digits. Usually little to no edema or inflammation is seen clinically. Reproduction of the pain with palpation to the intermetatarsal space is typical. Care must be taken to press in the intermetatarsal space and avoid the metatarsal heads.

**Clinical Maneuvers (Pathway 4, Node 3)**

Various clinical maneuvers have been described to assist the clinician in the diagnosis of Morton's neuroma. The patient may demonstrate a Mulder's sign, elicited by squeezing the forefoot and applying plantar and dorsal pressure. A positive test result consists of a click or pop that can be felt or heard; this can be painful to the patient. Symptoms of Morton's neuroma may be replicated through the Gauthier's test, in which the forefoot is squeezed and medial to lateral pressure is applied. Brakowski described a test that involves hyperextending the toes and rolling the thumb of the examiner in the area of symptoms. This maneuver may reveal a tender, thickened, longitudinal mass. Patients with Morton's neuroma also may demonstrate Tinel's sign and Valleix phenomenon.

**Diagnostic Testing (Pathway 4, Node 4)**

Diagnostic testing for a Morton's neuroma may include plain radiography, ultrasound, and magnetic resonance imaging (MRI).

Radiographs should be routinely ordered to rule out musculoskeletal pathology. Neuromas will not be visible on radiographs. Although increased proximity of the adjacent metatarsal heads has been thought to result in more pressure on the intermetatarsal nerve, Grace and colleagues found no statistically significant relationship between radiographic findings and the clinical presence of neuromas.

Ultrasound also has been recommended for diagnostic evaluation of the interspaces. A neuroma will appear as an ovoid mass with hypoechoic signal. This mass will be parallel to the long axis of the metatarsals and is best observed on the coronal view. MRI can be a useful diagnostic tool, but it should be reserved for atypical presentations or to rule out multiple neuromas. The neuroma is best identified on T1 weighted images. It will be revealed as a well-demarcated mass with low signal intensity.

**Differential Diagnosis (Pathway 4, Node 5)**

The diagnosis of Morton's neuroma requires a careful clinical history correlated with the condition's unique set of characteristics found on examination. Care must be taken to rule out other possible etiologies of symptoms in this area of the foot. The differential diagnosis of Morton's neuroma includes:

- Stress fracture
- Neoplasm (e.g., rheumatoid nodule)
- Bursitis
- Metatarsophalangeal joint (MPJ) pathology
- Metabolic neuropathy
- Fibromyalgia and other chronic pain syndromes

**Diagnosis (Pathway 4, Node 6)**

The diagnosis of Morton's neuroma is primarily a clinical diagnosis that is reached after examination and diagnostic testing have ruled out other possible etiologies of symptoms.

**Initial Treatment Options (Pathway 4, Node 7)**

Nonsurgical care of Morton's neuroma is centered on alleviating pressure and irritation of the nerve. Initially, patients should wear shoes that have a wide toe box to allow the metatarsals to spread out. High-heel shoes should be avoided.

Metatarsal pads also can be beneficial. These pads, placed proximal to the metatarsal heads, help alleviate pressure on the nerve and assist in spreading out the metatarsals.

Injection therapy includes a variety of alternative approaches to nonsurgical treatment. A local anesthetic block can be used to provide some diagnostic information, but it has not been shown to be therapeutic. Corticosteroid injection is cited as having an 11% to 47% success rate, with multiple injections obtaining better results. Care should be taken to avoid overusing corticosteroid injections; the literature contains reports of atrophy of the plantar fat pad secondary to cortisone injections, as well as joint subluxation. Dilute alcohol injections (3 to 7 injections of 4% alcohol administered at 5 to 10 day intervals) has been associated with an 89% success rate, with 82% of patients achieving complete relief of symptoms. Several other investigators have verified the efficacy of sclerosing injections as a nonsurgical treatment alternative. Another injection modality involves injecting the nerve with vitamin B12 (cyanocobalamin); this has been discussed in the literature, but the effects observed may have been due to the preserving agent, benzyl alcohol. Phenol also has been reported as a safe and effective injection modality.

**Surgical Treatment Options (Pathway 4, Node 8)**

Excision of the affected portion of the nerve is perhaps the most common approach to neuroma surgery. Excision requires identifying the common digital portion of the nerve and following the structure to the proper digital branches. Care must be taken to avoid other structures in the area. Various surgical approaches have been used, the most common of which is a dorsal incision over the involved intermetatarsal space (see Figure 3 in the original guideline document). Plantar incisional approaches are most often used in revisionary procedures, although they also have been described as an initial surgical approach. Excision may also be elected when prior decompression surgery has failed to resolve symptoms.
Decompression of the intermetatarsal nerve through the use of endoscopic and minimally invasive techniques has been reported in recent years. Open decompression of the nerve by releasing the deep transverse intermetatarsal ligament and performing an external neurolysis has been described. In addition, transposition with nerve release has been shown to be useful.

Cryogenic neuroablation is a minimally invasive procedure that applies a temperature of -50°C to -70°C to the nerve. This results in Wallerian degeneration of the axons and myelin, while leaving the epineurium and perineurium intact. Preserving these structures helps prevent stump neuromas during nerve regeneration; this is the greatest advantage of cryogenic ablation. There are limitations of this procedure. The results are not permanent, and it is not as effective on larger neuromas or in the presence of thick fibrosis. Several investigators have advocated this technique.

**Continued Symptoms (Pathway 4, Node 9)**

All treatments may have complications, with either ineffective relief of symptoms or worsening of the condition. Careful reassessment in failed surgical management may reveal tarsal tunnel or other proximal nerve pathology. Complications of surgical procedures include infection, hematoma, stump neuroma formation, and chronic pain syndromes. Surgical failures may require more aggressive surgical intervention including plantar approach and implantation of the proximal portion of nerve into muscle.

**Clinical Algorithm(s)**

An algorithm is provided in the original guideline document for Morton's intermetatarsal neuroma.

**Evidence Supporting the Recommendations**

**Type of Evidence Supporting the Recommendations**

The type of supporting evidence is not specifically stated for each recommendation.

This clinical practice guideline is based upon consensus of current clinical practice and review of the clinical literature.

**Benefits/Harms of Implementing the Guideline Recommendations**

**Potential Benefits**

Appropriate diagnosis and treatment of Morton's intermetatarsal neuroma

**Potential Harms**

- Care should be taken to avoid overusing corticosteroid injections; the literature contains reports of atrophy of the plantar fat pad secondary to cortisone injections, as well as joint subluxation.
- All treatments may have complications, with either ineffective relief of symptoms or worsening of the condition.
- Complications of surgical procedures include infection, hematoma, stump neuroma formation, and chronic pain syndromes.

**Implementation of the Guideline**

**Description of Implementation Strategy**

An implementation strategy was not provided.

**Implementation Tools**

Clinical Algorithm

Foreign Language Translations

Patient Resources

*For information about availability, see the Availability of Companion Documents and Patient Resources fields below.*

**Institute of Medicine (IOM) National Healthcare Quality Report Categories**

**IOM Care Need**

Getting Better

Living with Illness

**IOM Domain**

Effectiveness

**Identifying Information and Availability**

**Bibliographic Source(s)**

Stress fracture
Bursitis
Fibromyalgia and other chronic pain syndromes
Neoplasm (e.g., rheumatoid nodule)

Adaptation
Not applicable: The guideline was not adapted from another source.

Date Released
2009 Mar-Apr

Guideline Developer(s)
American College of Foot and Ankle Surgeons - Medical Specialty Society

Source(s) of Funding
American College of Foot and Ankle Surgeons

Guideline Committee
Clinical Practice Guideline Forefoot Disorders Panel

Composition of Group That Authored the Guideline
Clinical Practice Guideline Forefoot Disorders Panel: James L. Thomas, DPM, (Chair), Jacksonville, FL; Edwin L. Blitch, IV, DPM, Charleston, SC; D. Martin Chaney, DPM, San Antonio, TX; Kris A. Dinucci, DPM, Scottsdale, AZ; Kimberly Eickmeier, DPM, Champaign, IL; Laurence G. Rubin, DPM, Mechanicsville, VA; Mickey D. Stapp, DPM, Augusta, GA; and John V. Vanore, DPM, Gadsden, AL

Financial Disclosures/Conflicts of Interest
Not stated

Guideline Status
This is the current release of the guideline.

Guideline Availability
Electronic copies: Available in Portable Document Format (PDF) from the American College of Foot and Ankle Surgeons Web site.

Availability of Companion Documents
None available

Patient Resources
The following is available:


Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC Status
This NGC summary was completed by ECRI Institute on March 12, 2010. The information was verified by the guideline developer on April 14, 2010.

Copyright Statement
Please contact the American College of Foot and Ankle Surgeons (ACFAS) for permission to reproduce.

Disclaimer

NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
Metabolic neuropathy
Metatarsophalangeal joint (MPJ) pathology

Fibromyalgia and other chronic pain syndromes

Disclaimer
Source(s) of Funding
Guideline Developer(s)
Adaptation

IOM Domain
IOM Care Need
Description of Implementation Strategy

Description of Methods Used to Formulate the Recommendations

Description of the Methods Used to Analyze the Evidence

Methods Used to Collect/Select the Evidence

Methodology

Major Outcomes Considered

Target Population

Clinical Specialty

Guideline Status

This is the current release of the guideline.

Not stated

John V. Vanore, DPM, Gadsden, AL
Eickmeier, DPM, Champaign, IL; Laurence G. Rubin, DPM, Mechanicsville, VA; Mickey D. Stapp, DPM, Augusta, GA; and

Clinical Practice Guideline Forefoot Disorders Panel

An implementation strategy was not provided.

None available

Electronic copies: Available in Portable Document Format (PDF) from the

NGC banner

Foot and Ankle Surgeons consumer Web site

Getting Better

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty
societies, relevant professional associations, public or private organizations, other government agencies, health care
organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to
determine that they meet the NGC Inclusion Criteria which may be found at http://www.guide line.gov/about/inclusion-
criteria.aspx.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or
effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and
opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of
NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for
advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.